CA1262095A - Methode et compose pour lutter contre la douleur et la depression en procurant une sedation - Google Patents

Methode et compose pour lutter contre la douleur et la depression en procurant une sedation

Info

Publication number: CA1262095A
Authority: CA; Canada
Prior art keywords: serotonin; composition; pharmaceutically acceptable; trazodone; pain
Prior art date: 1985-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000504993A

Other languages

English (en)

Inventor

Martin G. Crosby

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SEROTONIN INDUSTRIES OF CHARLESTON A LP

Original Assignee

SEROTONIN INDUSTRIES OF CHARLESTON A LP

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-03-26

Filing date

1986-03-25

Publication date

1989-10-03

1985-07-16 Priority claimed from US06/755,367 external-priority patent/US4596807A/en

1986-03-25 Application filed by SEROTONIN INDUSTRIES OF CHARLESTON A LP filed Critical SEROTONIN INDUSTRIES OF CHARLESTON A LP

1989-10-03 Application granted granted Critical

1989-10-03 Publication of CA1262095A publication Critical patent/CA1262095A/fr

Status Expired legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 63
208000002193 Pain Diseases 0.000 title claims abstract description 46
230000036407 pain Effects 0.000 title claims abstract description 34
206010039897 Sedation Diseases 0.000 title claims abstract description 14
230000036280 sedation Effects 0.000 title claims abstract description 14
238000000034 method Methods 0.000 title description 10
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 145
229940076279 serotonin Drugs 0.000 claims abstract description 71
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 30
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims abstract description 29
229960003991 trazodone Drugs 0.000 claims abstract description 27
239000002243 precursor Substances 0.000 claims abstract description 24
230000003533 narcotic effect Effects 0.000 claims abstract description 21
229960004799 tryptophan Drugs 0.000 claims abstract description 21
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims abstract description 15
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims abstract description 13
229960002888 oxitriptan Drugs 0.000 claims abstract description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 44
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 42
150000003839 salts Chemical class 0.000 claims description 33
229940011671 vitamin b6 Drugs 0.000 claims description 21
235000008160 pyridoxine Nutrition 0.000 claims description 19
239000011677 pyridoxine Substances 0.000 claims description 19
229960005070 ascorbic acid Drugs 0.000 claims description 18
235000010323 ascorbic acid Nutrition 0.000 claims description 18
239000011668 ascorbic acid Substances 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 17
210000004556 brain Anatomy 0.000 claims description 16
230000015572 biosynthetic process Effects 0.000 claims description 10
239000007788 liquid Substances 0.000 claims description 7
239000008298 dragée Substances 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 5
239000000829 suppository Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
229940102223 injectable solution Drugs 0.000 claims 2
230000000202 analgesic effect Effects 0.000 abstract description 6
230000003389 potentiating effect Effects 0.000 abstract description 4
150000001875 compounds Chemical class 0.000 description 17
238000002560 therapeutic procedure Methods 0.000 description 17
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 13
239000004081 narcotic agent Substances 0.000 description 13
238000007726 management method Methods 0.000 description 11
239000003814 drug Substances 0.000 description 10
230000007958 sleep Effects 0.000 description 9
238000011282 treatment Methods 0.000 description 9
208000000094 Chronic Pain Diseases 0.000 description 8
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
229960003406 levorphanol Drugs 0.000 description 8
229940079593 drug Drugs 0.000 description 7
229960005181 morphine Drugs 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 6
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
229920002472 Starch Polymers 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
239000002775 capsule Substances 0.000 description 6
230000001276 controlling effect Effects 0.000 description 6
-1 e.g. Chemical class 0.000 description 6
230000006872 improvement Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
230000000977 initiatory effect Effects 0.000 description 5
229940090044 injection Drugs 0.000 description 5
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
229940000681 5-hydroxytryptophan Drugs 0.000 description 4
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
229930003268 Vitamin C Natural products 0.000 description 4
239000002253 acid Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
230000033444 hydroxylation Effects 0.000 description 4
238000005805 hydroxylation reaction Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
235000019154 vitamin C Nutrition 0.000 description 4
239000011718 vitamin C Substances 0.000 description 4
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 3
239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
208000020401 Depressive disease Diseases 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
208000005298 acute pain Diseases 0.000 description 3
238000011360 adjunctive therapy Methods 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
239000002585 base Substances 0.000 description 3
230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
235000020426 cherry syrup Nutrition 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
238000000576 coating method Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229960002464 fluoxetine Drugs 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
229910052742 iron Inorganic materials 0.000 description 3
230000007774 longterm Effects 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000932 sedative agent Substances 0.000 description 3
230000001624 sedative effect Effects 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
230000002936 tranquilizing effect Effects 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000002720 Malnutrition Diseases 0.000 description 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
102000005506 Tryptophan Hydroxylase Human genes 0.000 description 2
108010031944 Tryptophan Hydroxylase Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
239000003420 antiserotonin agent Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
208000021822 hypotensive Diseases 0.000 description 2
230000001077 hypotensive effect Effects 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000012153 long-term therapy Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000001071 malnutrition Effects 0.000 description 2
235000000824 malnutrition Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
238000013059 nephrectomy Methods 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
208000015380 nutritional deficiency disease Diseases 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 2
235000020323 palazzo Nutrition 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
239000011764 pyridoxine hydrochloride Substances 0.000 description 2
229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
208000019116 sleep disease Diseases 0.000 description 2
IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000003204 tranquilizing agent Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000019158 vitamin B6 Nutrition 0.000 description 2
239000011726 vitamin B6 Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
DFGNDJBYANKHIO-INIZCTEOSA-N (2s)-2-azaniumyl-3-(5-phenylmethoxy-1h-indol-3-yl)propanoate Chemical compound C1=C2C(C[C@H]([NH3+])C([O-])=O)=CNC2=CC=C1OCC1=CC=CC=C1 DFGNDJBYANKHIO-INIZCTEOSA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
GKECDORWWXXNRY-UHFFFAOYSA-N 2h-pyridin-3-one Chemical compound O=C1CN=CC=C1 GKECDORWWXXNRY-UHFFFAOYSA-N 0.000 description 1
JCQLPDZCNSVBMS-UHFFFAOYSA-N 5-phenylmethoxy-1h-indole Chemical compound C=1C=C2NC=CC2=CC=1OCC1=CC=CC=C1 JCQLPDZCNSVBMS-UHFFFAOYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010001605 Alcohol poisoning Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010010075 Coma hepatic Diseases 0.000 description 1
206010010305 Confusional state Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010020400 Hostility Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021135 Hypovitaminosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
102000010909 Monoamine Oxidase Human genes 0.000 description 1
108010062431 Monoamine oxidase Proteins 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
206010034719 Personality change Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
102000014961 Protein Precursors Human genes 0.000 description 1
108010078762 Protein Precursors Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
230000002908 adrenolytic effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940086708 ascorbic acid 250 mg Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
UUVBYOGFRMMMQL-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca].OP(O)(O)=O UUVBYOGFRMMMQL-UHFFFAOYSA-N 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
238000011281 clinical therapy Methods 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000011340 continuous therapy Methods 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000002950 deficient Effects 0.000 description 1
229940080861 demerol Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
201000001059 hepatic coma Diseases 0.000 description 1
208000007386 hepatic encephalopathy Diseases 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000006207 intravenous dosage form Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000003880 negative regulation of appetite Effects 0.000 description 1
210000000478 neocortex Anatomy 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229940085033 nolvadex Drugs 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
229940124583 pain medication Drugs 0.000 description 1
230000037325 pain tolerance Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940107333 phenergan Drugs 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
150000003227 pyridoxines Chemical class 0.000 description 1
210000001609 raphe nuclei Anatomy 0.000 description 1
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
230000004799 sedative–hypnotic effect Effects 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229940125725 tranquilizer Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229940072690 valium Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
229960002791 zimeldine Drugs 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA000504993A 1985-03-26 1986-03-25 Methode et compose pour lutter contre la douleur et la depression en procurant une sedation Expired CA1262095A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US71600085A	1985-03-26	1985-03-26
US716,000		1985-03-26
US755,367		1985-07-16
US06/755,367 US4596807A (en)	1985-03-26	1985-07-16	Method and compositions for controlling pain, depression and sedation

Publications (1)

Publication Number	Publication Date
CA1262095A true CA1262095A (fr)	1989-10-03

Family

ID=27109451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000504993A Expired CA1262095A (fr)	1985-03-26	1986-03-25	Methode et compose pour lutter contre la douleur et la depression en procurant une sedation

Country Status (3)

Country	Link
CA (1)	CA1262095A (fr)
ES (1)	ES8800045A1 (fr)
PT (1)	PT82268B (fr)

1986
- 1986-03-25 CA CA000504993A patent/CA1262095A/fr not_active Expired
- 1986-03-25 PT PT8226886A patent/PT82268B/pt active IP Right Revival
- 1986-03-26 ES ES553457A patent/ES8800045A1/es not_active Expired

Also Published As

Publication number	Publication date
ES553457A0 (es)	1987-11-01
PT82268B (pt)	1988-02-17
PT82268A (en)	1986-04-01
ES8800045A1 (es)	1987-11-01

Legal Events

Date	Code	Title	Description
1996-04-03	MKLA	Lapsed

Publication	Publication Date	Title
EP0222782B1 (fr)	1994-11-09	Compositions pour maitriser la douleur, la depression et la sedation
US4698342A (en)	1987-10-06	Method and compositions for controlling pain, depression and sedation
AU730495B2 (en)	2001-03-08	Administration media for analgesic, antiinflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
US4843071A (en)	1989-06-27	Method and composition for treating obesity, drug abuse, and narcolepsy
JPH05507731A (ja)	1993-11-04	物質乱用障害の治療用医薬組成物
EP2717698A1 (fr)	2014-04-16	Antihistaminiques combinés à des compléments alimentaires pour améliorer la santé
JPS59193821A (ja)	1984-11-02	抗不安薬としてのフルオキセチンの使用法
Breivik et al.	1982	Clinical evaluation of combined treatment with methadone and psychotropic drugs in cancer patients
JP2005524629A (ja)	2005-08-18	体重、血中脂質レベルを減少させるため、並びに癌の予防および治療のためのホホバ製品
CN106265696A (zh)	2017-01-04	使用复合维生素b、c组合物促进胃肠系统动力的方法
EP0808166A1 (fr)	1997-11-26	Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports
JP2001518481A (ja)	2001-10-16	経口投与のためのセロトニン含有製剤及びその使用方法
Singer et al.	1985	Seizures due to theophylline overdose
Urwin et al.	1999	Fatal nefopam overdose.
HUP0203025A2 (hu)	2002-12-28	Migrén kezelése alfa-liponsav és származékainak alkalmazásával
KR101239379B1 (ko)	2013-03-05	Ｌ-트립토판을 위한 신규 제제
WO2001067890A2 (fr)	2001-09-20	Composition et procede de traitement de la prise de poids et de l'obesite attribuables a des medicaments psychotropes
Sim	1973	Methadone
WO2019100057A1 (fr)	2019-05-23	Utilisation de morphinanes pour traiter la dépendance à la cocaïne, le prurit et les troubles épileptiques
JPS62502798A (ja)	1987-11-12	痛み、抑うつ症および鎮静を制御する方法および組成物
JPH0518811B2 (fr)	1993-03-15
EP1374873B1 (fr)	2005-04-27	Utilisation de la n-acetyl-d-glucosamine dans la preparation de compositions pharmaceutiques utilisees dans la suppression des effets secondaires causes par la radiotherapie et la chimiotherapie
KR20070116087A (ko)	2007-12-06	고혈압 치료용 약제의 제조를 위한 염산의 이용
TWI657817B (zh)	2019-05-01	2-羥基-9-(4-羥基苯基)-1h-萘嵌苯-1-酮之應用
Tennant Jr	1983	(−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids